|
Joachim (Aki) von Roy
Aki von Roy is a bio-entrepreneur who has focused his activities on New Zealand and Australian opportunities. Aki is known in the New Zealand biotechnology community for his role in leading a $12 million Series A fund raising for Proacta and for helping other biotechnology start-ups, such as CoDa Therapeutics, Corra Life Science, Biomatters and PhotoNZ to develop their business concepts.
He is a director of Biomatters Ltd, Corra Life Sciences, Phytomedics, Inc., Wool Equities Ltd, Orico Ltd, Paraco Ltd, Keratec Ltd, and Roberts & von Roy Associates Ltd, and Chairman of White Biotechnology Pty Ltd and Phylogica. Aki is a partner of Inventages Venture Capital Investments, a venture capital company based in Switzerland and the Bahamas that manages the recently launched $150 million food, agbiotech and health fund BioPacificVentures, a collaboration with New Zealand-based venture capitalist Direct Capital Private Equity Ltd and AgResearch Ltd. He is also a member of BioPacificVentures Investment Committee and an advisor to the Foundation for Research, Science and Technology. He is a German national and is the former European president of pharmaceutical giant Bristol-Myers Squibb. Aki was the New Zealand managing director for German drug company Schering AG in 1970/71 and after that went to Sweden, the US and eventually back to Germany to co-chair Schering AG’s home market. In 1984, he joined Squibb (von Heyden) to bring the two companies together and took over responsibility for Germany, Austria, Switzerland and Eastern Europe. Shortly after the Bristol-Myers merger with Squibb (1989) he became president for Europe, responsible for US$ 2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. In 1997, he retired from BMS to establish Roberts & van Roy Associates, a private investment company specialising in health and related matters. He is now actively involved in creating a sustainable NZ/Australian biotech industry.
Steven Gillis PhD
Andy Gearing PhD
Andy Gearing is based in Melbourne, Australia, where he is the chief executive of Biocommsquare Pty Ltd, an international life sciences business development company. Dr. Gearing has a successful track record in research management and business development in the European biotechnology sector. He moved to Australia in 2001 to establish Biocomm Services, which has provided services to many prestigious academic institutions as well as private and listed biotechnology clients in Australia, New Zealand, Japan, North America and Europe. Under Dr. Gearing’s management, Biocomm Services successfully completed eleven international licensing transactions for its clients and established three new biotechnology companies. Dr. Gearing is a director of Cryptopharma Pty Ltd and CNSBio Pty Ltd.
Daniel Mahnert-Lueg BSc MID MBADaniel Mahnert-Lueg is a German national who is currently based in Shanghai. He is qualified BSc MID MBA and has international experience in marketing and investment.
|
Steve Gillis has served as Director of Genesis since 1993. Dr Gillis is a venture partner with ARCH Venture Partners in Seattle, WA. He was a founder of Immunex Corporation, where he held multiple positions from 1981 to 1994, including acting Chief Executive Officer and Chairman. Dr Gillis co-founded Corixa Corporation in 1994, serving Chief Executive Officer and as a director since that time, and chaired the Corixa Corporation board since March 1999. Corixa Corporation was acquired by GlaxoSmithKline in July 2005. He is a director of Trubion Pharmaceuticals (TRBN), Variation Biotechnologies, Limerick NeuroSciences, Magen BioSciences, Accelerator, and Surface Logix. He serves as director and Chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST.